News Astellas' Iveric takeover rewarded with FDA nod for GA drug The FDA has approved a new drug for sight-robbing disease geographic atrophy from Astellas, just a few weeks after the company
News Astellas cuts $5.9bn deal to buy Iveric Bio Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,
News FDA clears AZ's Imfinzi for aggressive lung cancer AstraZeneca's Imfinzi becomes the first cancer immunotherapy to be FDA-approved for limited-stage small cell lung cancer (LS-SCLC).
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
